Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 32 recruiting now early-phase tilt

Long COVID: early-phase trial registry

32 of 51 indexed Long COVID trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #274 of 28,707 conditions by registered trial count.

51 US clinical trials · 32 currently recruiting · #274 of 28,707 conditions by registered trial count

Long COVID: 51 US clinical trials tracked, 32 recruiting.

Long COVID is the subject of 51 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Duke University, running 5 of these trials.

Enrollment posture brief

Registry condition long-covid

OPEN 32 | RECR 63% | LATE 2 | EARLY 21 | RANK #274 | SPON 5

Nearest open-share peer: Caregiver Burden (63% recruiting · 43 trials)

Long COVID (this)63%Peripheral Artery Disease54.9%Idiopathic Pulmonary Fibrosi42.3%Acute Pain25.5%Congestive Heart Failure15.4%
Open-enrollment share among volume-matched conditions near Long COVID

Long COVID lists 32 open slots (63% of 51 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Long COVID on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Long COVID is recruiting above its size-band peers.

    32 of 51 indexed trials (62.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Long COVID trials is spread across many organizations.

    Duke University accounts for 5 of 51 trials (9.8%). 35 distinct sponsors appear on at least one study for this condition label.

  3. Typical Long COVID enrolment sits around 90 participants.

    Median target enrolment is 90 among the 51 trials that report a genuine target (sentinel values excluded). 27 of those (52.9%) plan for fewer than 100 participants.

  4. Long COVID research is mostly interventional.

    47 interventional and 4 observational studies make up this index (92.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 218Phase 32

Open and recent trials

51 total, page 1 of 2

RECRUITING NA 100,500 participants

The Long COVID-19 Wearable Device Study

Scripps Translational Science Institute

NCT05741112

RECRUITING 600 participants

COVID-19 Outcome Prediction Algorithm

University of California, Los Angeles

NCT05471011

RECRUITING Phase 3 550 participants

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Wes Ely

NCT06631287

RECRUITING NA 400 participants

Long-Covid-19 Alleviation Through Learning Mindfulness Study

Columbia University

NCT07140094

RECRUITING Phase 3 348 participants

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

Douglas D. Fraser

NCT06928272

RECRUITING NA 300 participants

Long-term COVID and Rehabilitation

VA Office of Research and Development

NCT05373043

RECRUITING NA 224 participants

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

MaxWell Clinic

NCT06311435

RECRUITING Phase 2 208 participants

NE3107 in Adults With Neurological Symptoms of Long COVID

BioVie

NCT06847191

RECRUITING 200 participants

Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans

VA Office of Research and Development

NCT06932237

RECRUITING Phase 2 180 participants

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

Medical University of South Carolina

NCT05855369

RECRUITING NA 180 participants

Mind Body Intervention for Long COVID-19

Beth Israel Deaconess Medical Center

NCT06045338

RECRUITING Phase 2 160 participants

LIFT: Life Improvement Trial

Brigham and Women's Hospital

NCT06366724

RECRUITING NA 150 participants

Long COVID Immune Profiling

Vanderbilt University Medical Center

NCT06027255

RECRUITING Phase 2 150 participants

AT1001 for the Treatment of Long COVID

Massachusetts General Hospital

NCT05747534

RECRUITING Phase 1 120 participants

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Icahn School of Medicine at Mount Sinai

NCT06511050

RECRUITING NA 99 participants

Heat thErapy And mobiLity in COVID-19 Survivors

University of Nebraska

NCT06928116

RECRUITING Phase 2 90 participants

Antiviral Clinical Trial for Long Covid-19

Icahn School of Medicine at Mount Sinai

NCT06511063

RECRUITING Phase 2 60 participants

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

University of New Mexi

NCT06940609

RECRUITING NA 60 participants

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Vanderbilt University Medical Center

NCT05421208

RECRUITING Phase 1 60 participants

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

National Institute of Mental Health (NIMH)

NCT06920628

RECRUITING NA 60 participants

Improving Attention in Individuals With Long COVID-19

Shirley Ryan AbilityLab

NCT06503874

RECRUITING NA 55 participants

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Stanford University

NCT05833217

RECRUITING NA 50 participants

Water-based Activity to Enhance Recovery in Long COVID-19

VA Office of Research and Development

NCT06142253

RECRUITING NA 50 participants

tVNS in Long COVID-19

Icahn School of Medicine at Mount Sinai

NCT06585254

RECRUITING NA 45 participants

Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog

Mayo Clinic

NCT06614309

RECRUITING Phase 2 40 participants

A Study to Examine Anktiva for the Treatment of COVID-19.

ImmunityBio

NCT07123727

RECRUITING NA 30 participants

Long COVID Brain Fog: Cognitive Rehabilitation Trial

University of Alabama at Birmingham

NCT06095297

RECRUITING Early Phase 1 30 participants

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

University of Chicago

NCT06171152

RECRUITING NA 21 participants

Sauna for Long Covid

Massachusetts General Hospital

NCT05931497

RECRUITING NA 20 participants

CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19

University of California, San Francisco

NCT05530317

RECRUITING NA 20 participants

Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID

University of Louisville

NCT06883513

RECRUITING NA 10 participants

Acupuncture and Chinese Herbal Medicine for Long COVID

Southern California University of Health Sciences

NCT07285707

ACTIVE NOT RECRUITING Phase 2 1,000 participants

The Long COVID Treatment Trial

Scripps Translational Science Institute

NCT07128082

ACTIVE NOT RECRUITING Phase 2 470 participants

RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)

Duke University

NCT06404112

ACTIVE NOT RECRUITING Phase 2 361 participants

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

Duke University

NCT06404099

ACTIVE NOT RECRUITING NA 360 participants

RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

Duke University

NCT06404060

ACTIVE NOT RECRUITING Phase 2 200 participants

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Kanecia Obie Zimmerman

NCT06305793

ACTIVE NOT RECRUITING Phase 2 60 participants

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

University of Chicago

NCT04948203

ACTIVE NOT RECRUITING 41 participants

Pain in Long COVID-19: the Role of Sleep

Beth Israel Deaconess Medical Center

NCT05606211

ACTIVE NOT RECRUITING Phase 2 40 participants

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Timothy Henrich

NCT06161688

ACTIVE NOT RECRUITING Phase 2 36 participants

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Michael Peluso, MD

NCT05877508

ACTIVE NOT RECRUITING NA 21 participants

Fatigability in Long COVID-19

VA Office of Research and Development

NCT05699538

COMPLETED Phase 2 830 participants

RECOVER-SLEEP: Platform Protocol

Duke University

NCT06404086

COMPLETED NA 328 participants

RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

Duke University

NCT05965739

COMPLETED 239 participants

CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases

4YouandMe

NCT06907953

COMPLETED Phase 2 191 participants

Fluvoxamine for Long COVID-19

Washington University School of Medicine

NCT05874037

COMPLETED Phase 2 59 participants

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

Bateman Horne Center

NCT06316843

COMPLETED NA 40 participants

Qigong for Post Acute Sequelae of COVID-19 Infection

University of California, Davis

NCT05675995

COMPLETED NA 31 participants

Effect of Daily Walnut Consumption on Memory in Subjects With Long-COVID

University of California, Los Angeles

NCT07429903

COMPLETED Phase 2 17 participants

Nitrite Supplementation in Long COVID Patients

VA Office of Research and Development

NCT05618574

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 18
Phase 3 2

Named interventions

Most-linked intervention names on Long COVID records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Placebo Other
4 trials
Solriamfetol Placebo Drug
2 trials
Modafinil Placebo Drug
2 trials
Solriamfetol Drug
2 trials
Modafinil Drug
2 trials
Melatonin Drug
2 trials
Usual Care Behavioral
2 trials

US sites by state

Facility locations filed on Long COVID trials. A trial with sites in several states counts in each.

California 16 trials
New York 7 trials
Massachusetts 6 trials
Illinois 6 trials
Tennessee 5 trials
North Carolina 5 trials
Georgia 4 trials
Utah 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Long COVID page

51 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Long COVID condition card totals 51 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.